Survival outcomes with second-generation androgen receptor inhibitors for nmCRPC in older men

Pooled analysis of patient-level data from three randomised trials evaluated survival outcomes with second-generation androgen receptor inhibitors (ARIs) for nonmetastatic castration-resistant prostate cancer in patients aged 80 years or older. The median metastasis-free survival was 40 months in the pooled ARI-treated groups versus 22 months in the pooled placebo groups (aHR 0.37; 95% CI 0.28-0.47) and the median overall survival was 54 months versus 49 months, respectively (aHR 0.79; 95% CI 0.64-0.98). Grade 3 or worse AEs were reported for 55% in the pooled ARI-treated groups versus 41% in the pooled placebo groups. The authors conclude that these results support the use of ARIs for nmCPRC in older men.